
Keywords: ADT, androgen deprivation therapy; BPH, benign prostatic hyperplasia; CCL2, CC chemokine ligand 2; CRPC, castration-resistant prostate cancer; EMT, epithelial mesenchymal transition; IGF-IR, insulin-like growth factor I receptor; IL, interleukin; MDSCs, m